Thrasher, James

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 376

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes

Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Management and Education

Cited by 230

Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial

Brazg, R., Garg, S. K., Bhargava, A., Thrasher, J. R., Latif, K., Bode, B. W., Bailey, T. S., Horowitz, B. S., Cavale, A., Kudva, Y. C., et al. (2022) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchIntravenous Infusion Technology and Safety

Cited by 28